Cohance Lifesciences Limited — PPTs, 12-02-2025: Investor Presentation

**Financial Highlights**: Suven Pharmaceuticals reported a strong performance in Q3, with a 40% YoY revenue growth to ₹6,764 million and an adjusted EBITDA margin of 38.7%. For the 9-month period, revenues grew by 5% YoY to ₹17,691 million, with adjusted EBITDA margins at 34.8%. The Pharma CDMO segment was a key driver, achieving 101% YoY revenue growth in Q3 and 11% growth over 9M.

**Strategic Initiatives and Growth Drivers**: Suven aims to achieve $1 billion in revenue through a diversified strategy focusing on three pillars: Pharma CDMO, Specialty Chemicals CDMO, and APIs. The company is investing in differentiated modalities like ADCs and oligonucleotides, supported by a robust M&A strategy and enhanced R&D capabilities.

**Business Developments**: The merger with Cohance Lifesciences has progressed well, with 99.99% shareholder approval and a final NCLT hearing set for February. This merger is expected to enhance Suven's operational capabilities and market reach significantly.

**Market Position and Competitive Advantage**: Suven is positioned as a global leader in the CDMO space, with a solid foundation for growth through strategic partnerships, an expanding portfolio, and a focus on sustainable business practices.

**Investor Implications**: The combined entity is expected to deliver sustained growth, with strong cash flow generation and a debt-free balance sheet. The outlook remains positive, with continuous expansion opportunities in high-growth segments like ADCs and oligonucleotides. Investors should watch closely for growth acceleration projected from FY26 onwards.